FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281656472> ?p ?o ?g. }

• W4281656472 endingPage "9020" @default.
• W4281656472 startingPage "9020" @default.
• W4281656472 abstract "9020 Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed by cancer and stromal cells of many solid tumors. The IL-1 pathway is active in tumors and upregulated in response to chemotherapy. IL1RAP interacts with IL-1R1 and modulates downstream factors (e.g. IL-6, IL-8) and CRP level. Nadunolimab (CAN04), a fully humanized ADCC-enhanced IgG1 antibody, targets IL1RAP and blocks IL-1α and IL-1β signaling. Here, results are reported from the phase 1/2a clinical trial CANFOUR evaluating nadunolimab combined with CG in NSCLC. Methods: Patients (pts) with unresectable, locally advanced or metastatic NSCLC, progressed on pembrolizumab or in first line for advanced disease, were eligible. Pts received 1 (n =17), 2.5 (n = 3) or 5 mg/kg (= 13) nadunolimab given Q1W in Cycle 1 and Q2W from Cycle 2, combined with standard CG. Due to risk of infusion-related reactions, a priming dose of 0.5 mg/kg nadunolimab was given one week before CG. Primary objective was safety; secondary objectives included ORR, PFS and OS, and exploratory objectives included effects on serum and tumor tissue biomarkers. Results: Thirty-three pts were enrolled: median age 64 years (39-77), 30% female, 42% ECOG 0, 55% non-squamous histology, 82% stage IV, 45% received previous pembrolizumab monotherapy. Treatment-related adverse events of grade≥3 were observed in 73% of pts, including neutropenia (58%), febrile neutropenia (9%), thrombocytopenia (30%) and anemia (18%). Neutropenia could be managed by G-CSF. Thirty pts received combination therapy and were included in the efficacy analysis. Three pts did not receive chemotherapy due to clinical deterioration (n = 2) or consent withdrawal (n = 1). ORR was 53% (95% CI 34-72%), disease control rate 80% (61-92%) and median duration of response 5.5 months (3.7-7.0) with 23% of pts still on treatment. The lower limit of the 95% CI for the observed ORR excludes the pre-specified 30%. ORR in pts with squamous histology was 46% and non-squamous 56%. Median PFS was 6.7 months (5.5-7.3) and median OS 13.7 months. The neutrophil-lymphocyte ratio was reduced throughout the trial and was driven by the reduction in circulating neutrophil numbers. IL1RAP expression on both cancer and stromal cells was confirmed in tumor biopsies. Conclusions: Nadunolimab combined with CG shows manageable safety and promising efficacy with a response rate of 53% in NSCLC pts. Nadunolimab is currently evaluated in several clinical trials investigating chemotherapy or IO combinations, including carboplatin and pemetrexed in non-squamous NSCLC. Clinical trial information: NCT03267316." @default.
• W4281656472 created "2022-06-13" @default.
• W4281656472 creator A5006528937 @default.
• W4281656472 creator A5010064853 @default.
• W4281656472 creator A5018082957 @default.
• W4281656472 creator A5024821812 @default.
• W4281656472 creator A5028565439 @default.
• W4281656472 creator A5052765751 @default.
• W4281656472 creator A5062634793 @default.
• W4281656472 creator A5068017392 @default.
• W4281656472 date "2022-06-01" @default.
• W4281656472 modified "2023-10-18" @default.
• W4281656472 title "Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC)." @default.
• W4281656472 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9020" @default.
• W4281656472 hasPublicationYear "2022" @default.
• W4281656472 type Work @default.
• W4281656472 citedByCount "3" @default.
• W4281656472 countsByYear W42816564722022 @default.
• W4281656472 countsByYear W42816564722023 @default.
• W4281656472 crossrefType "journal-article" @default.
• W4281656472 hasAuthorship W4281656472A5006528937 @default.
• W4281656472 hasAuthorship W4281656472A5010064853 @default.
• W4281656472 hasAuthorship W4281656472A5018082957 @default.
• W4281656472 hasAuthorship W4281656472A5024821812 @default.
• W4281656472 hasAuthorship W4281656472A5028565439 @default.
• W4281656472 hasAuthorship W4281656472A5052765751 @default.
• W4281656472 hasAuthorship W4281656472A5062634793 @default.
• W4281656472 hasAuthorship W4281656472A5068017392 @default.
• W4281656472 hasConcept C121608353 @default.
• W4281656472 hasConcept C126322002 @default.
• W4281656472 hasConcept C143998085 @default.
• W4281656472 hasConcept C2776256026 @default.
• W4281656472 hasConcept C2776694085 @default.
• W4281656472 hasConcept C2777063308 @default.
• W4281656472 hasConcept C2778850193 @default.
• W4281656472 hasConcept C2780258809 @default.
• W4281656472 hasConcept C2781190966 @default.
• W4281656472 hasConcept C31760486 @default.
• W4281656472 hasConcept C71924100 @default.
• W4281656472 hasConcept C90924648 @default.
• W4281656472 hasConceptScore W4281656472C121608353 @default.
• W4281656472 hasConceptScore W4281656472C126322002 @default.
• W4281656472 hasConceptScore W4281656472C143998085 @default.
• W4281656472 hasConceptScore W4281656472C2776256026 @default.
• W4281656472 hasConceptScore W4281656472C2776694085 @default.
• W4281656472 hasConceptScore W4281656472C2777063308 @default.
• W4281656472 hasConceptScore W4281656472C2778850193 @default.
• W4281656472 hasConceptScore W4281656472C2780258809 @default.
• W4281656472 hasConceptScore W4281656472C2781190966 @default.
• W4281656472 hasConceptScore W4281656472C31760486 @default.
• W4281656472 hasConceptScore W4281656472C71924100 @default.
• W4281656472 hasConceptScore W4281656472C90924648 @default.
• W4281656472 hasIssue "16_suppl" @default.
• W4281656472 hasLocation W42816564721 @default.
• W4281656472 hasOpenAccess W4281656472 @default.
• W4281656472 hasPrimaryLocation W42816564721 @default.
• W4281656472 hasRelatedWork W1968954703 @default.
• W4281656472 hasRelatedWork W1973241390 @default.
• W4281656472 hasRelatedWork W1987606751 @default.
• W4281656472 hasRelatedWork W1990777236 @default.
• W4281656472 hasRelatedWork W2003291927 @default.
• W4281656472 hasRelatedWork W2062191467 @default.
• W4281656472 hasRelatedWork W2126539868 @default.
• W4281656472 hasRelatedWork W2160583837 @default.
• W4281656472 hasRelatedWork W2168653455 @default.
• W4281656472 hasRelatedWork W25071997 @default.
• W4281656472 hasVolume "40" @default.
• W4281656472 isParatext "false" @default.
• W4281656472 isRetracted "false" @default.
• W4281656472 workType "article" @default.